

DETERMINING SUITABLE SUBSTRATE CONVERSION FOR ENZYMATICAASSAYS IN HIGH- THROUGHPUT SCREENING**Lakhan D. Baheti* and Rucha S. Tiwari**

Mahatma Gandhi Vidyamandir's Pharmacy College, Panchavati Nashik-422003.

Article Received on
03 Jan. 2023,Revised on 24 Jan. 2023,
Accepted on 13 Feb. 2023

DOI: 10.20959/wjpr20234-27318

Corresponding Author*Lakhan D. Baheti**

Mahatma Gandhi

Vidyamandir's Pharmacy

College, Panchavati Nashik-
422003.**ABSTRACT**

It's generally accepted that the conversion of substrate should be kept at lower than 10% of the total substrate used when studying enzyme kinetics. still, 10 or lower substrate conversion frequently won't produce sufficient signal changes needed for robust HTS. To increase the signal- to- background rate, HTS is frequently performed at advanced than 10% substrate conversion. Because the consequences of high substrate conversion are inadequately understood, the webbing results are occasionally questioned by enzymologists. The quality of an assay is judged by the capability to describe an asset under HTS conditions, which depends on the robustness of the primary discovery signal (Z factor) and the perceptivity to an asset. The assay perceptivity

to an asset is reflected in the observed IC₅₀ value or percent inhibition at a fixed emulsion attention when single- point data are collected. The major concern for an enzymatic assay under high substrate conversion is that the perceptivity of the screen may be compromised. Here we decide the relationship between the IC₅₀ value for a given asset and the chance of substrate conversion using a first- order kinetic model under conditions that observe Henri-Michaelis- Menten kinetics. The deduced theory was further vindicated experimentally with a cAMP-dependent protein kinase. This model provides guidance for assay inventors to choose an applicable substrate conversion in designing an enzymatic assay, balancing the requirements for robust signal and perceptivity to impediments. This composition reviews different possibilities for conducting enzymatic assays on microchip platforms, along with implicit advantages, limitations, and named exemplifications of similar biochips. Enzyme-grounded chips combine the logical power and reagent frugality of microfluidic bias with the selectivity and modification features of biocatalytic responses. "Lab-on- chip" bias therefore allows enzymatic assays to be performed more fleetly, fluently, and economically. Similar

assays generally calculate on- chip mixing and responses (of the substrates and enzymes) in connection to separations (of the substrates or products). The consummation of on- chip enzymatic assays therefore require understanding of how enzymatic responses bear on a small scale and can be connived with separation microchips, and how the microfluidics can be acclimated to suit the conditions of particular enzymatic assays. The thing is to gain sufficient response times, without compromising the quality of the logical separation. The versatility of similar on- chip enzymatic assays offer great promise for decentralised testing of clinically or environmentally important substrates.

KEYWORDS: HTS, enzymatic assay, screening, Extracellular, Amylase, Lipase, Protease.

INTRODUCTION

Recent studies show that 47% of all the put-up small molecule medicines act on enzymes.^[1] Because enzymes are similar important medicine targets, it isn't a surprise that a large portion of high- throughput screening (HTS) has been performed with enzymes.^[2-4] There has been a wealth of knowledge about enzyme kinetics since 1902 when Henri concluded what's now most consistently cited as the Michaelis- Menten Equation.^[5-7] Both lightning equilibrium analysis and steady- state analysis of enzyme kinetic studies was predicated on one substrate enzyme systems. A multisubstrate enzyme system, similar as kinases that use a protein/ peptide and ATP as substrates, can be experimentally manipulated so that the substrate to be studied is set at a concentration that is much lower than the other substrates to attain a pseudo-one-substrate system.^[8] This pseudo one-substrate system allows the operation of theory deduced from one substrate systems. In HTS for enzyme impediments, lookers of thousands to millions of compounds at a fixed concentration are assayed with substrate and enzyme at fixed attention under identical assay conditions. In a typical HTS operation, only 1 data point in the response course rather than the whole response progression arc is measured to reduce the cost. In discrepancy, entomologists dealing with a few compounds usually measure the whole response progression wind to acquire the earliest velocity when no substrate has been depleted due to its conversion to products.

It's a general rule that an assay should be designed to give a measured velocity as close to foremost velocity as possible if only 1 point in the response progression wind is measured. For a simple first- order response converting substrate to product, single- point Dimension at 10 substrate conversion would give a velocity that is 5 lower than the true velocity. accordingly, staying at or below revolution will give results close to the true earliest velocity. In numerous

assay formats, 10 or lower substrate conversion will not produce sufficient signal changes to be detected. prototypes of these assays are mobility shift assays similar as the kinase assay employing Calliper microfluidic systems where the substrate and product fluoresce at resembling intensity, luminescence polarisation assays where substrate is fluorescently labelled and the product widely binds to large polymeric acceptors or globules, and kinase assays wherein the change in ATP concentration is detected by fluorescence using luciferase and luciferin. To increase the primary discovery signal- to- background rate (and hence the Z factor 9), assay formulators frequently ignore the 10 rule and perform the assay at advanced substrate conversion.^[9,10] The benefit of increased substrate conversion can be appreciated in a hypothetical script as shown in Table 1.

Table 1: We assume an assay with 6% coefficient of variation (CV) in the measurement of all the signals. We further assume the assay has a background (B) of 100 counts and a signal (S) of 150 counts (100 counts from the background and 50 counts from the product) at 10% substrate conversion. This assay has a Z factor of 0.1 that is unacceptable for screening. If we increase the substrate conversion by a factor of 5, the signal (S) will increase to 350 counts (100 counts from background and 250 counts from the 5-fold increased product). With the 5-fold increase in substrate conversion, the Z factor of this assay increased from 0.1 to 0.676.

S	B	CV	$\sigma(S)$	$\sigma(B)$	Z
150	100	6%	9	6	0.1
350	100	6%	21	6	0.676

Nevertheless, the graces of this practice are frequently questioned by some enzymologists when the webbing results are in question. Because of the lack of theoretical analysis of what consequences will come down when substrate conversion is advanced than 10, and our frequent use of high substrate conversion when using the microfluidic screening approaches, we concluded equations that reveal the relationship between the single time point measured IC50 values and the substrate conversion predicated on the first- order substrate reduction response progression curvature. Because an enzyme catalysed one-substrate response that obeys the Henri- Michaelis-Menten equation will suffer the most substrate reduction under first- order substrate reduction kinetics, our equation reveals the maximum IC50 changes at specific substrate conversion relative to the IC50 value at no substrate conversion.

Microfabricated microfluidic logical bias, integrating multiple samples running processes with the factual dimension step, are of considerable recent interest.^[11,12] For egregious reasons, similar bias is ascertained to as “Lab- on-a-chip” bias. The advantages of similar logical microsystems, including speed, high performance, integration, versatility, negligible sample/reagent consumption, miniaturization, and robotization, have been well proved.^[11–13] The end of the present composition is to bandy the operation of enzyme- grounded microchip bias and to review recent sweats towards the development of similar biochips. Enzymes can specifically convert 10² – 10⁵ substrates operative clues to product within 1s. Because of these catalytic(modification) and selectivity parcels, enzymes have Setup wide use in chemical analysis, including conventional inflow- injection analysis^[14] and traditional CE systems.^[15,16] Microchip bias have proven them characters largely seductive for conducting enzymatic assays.

On- chip enzymatic assays belong to the class of micro-chip derivatization protocols in which a nondetectable species is converted to a sensible one.^[17] While early microchip derivatization/ separation assays have concentrated on chemical responses, the use of enzymes can conduct high selectivity into microchip bias, and expand their compass towards analytically important substrates. In addition to assays of substrates, enzyme- grounded microchip bias offer accessible determination of enzyme inhibit bluffs (e.g., poisons), measures of enzyme conditioning, or forrelating enzymes among promised factors Chipbias offer great pledge for downscaling enzymaticassays to the nanoliter position. The quantum of enzyme consumed in microchip protocols is therefore reduced ca. four orders of magnitude overconventional assays. similar reagent frugality, essential to microchip systems, obvi ates the need for enzyme immobilization (and related stabilization issues) and addresses the high cost of numerous enzymes, cofactors, or substrates. Combining this capability of microchips to handle nanoliter volumes, with their versatility and speed, makes them ideal vehicles for enzymatic assays. similar use of microchips may not only re place conventional (batch or inflow) operations, but also provides unique openings for conducting enzymatic assays. also, enzyme- grounded biochips could contend with conventional biosensors in terms of performance, speed, sample volume, and size.




Figure 1: Layout of the separation microchips with (A) post column and (B) precolumn enzymatic reactions for measuring the corresponding substrates.

Screening

Screening delivered by Sadler (1996) is that it's a process involving the determination of whether or not an individual offer. Screening is thus a decision-making process that is initiated during the early stage of the development of an offer. Screening styles are veritably useful tools for examining simulations models that involved a large number of factors.^[18-21] This screening stage should involve a minimal number of trials and shouldn't take important computing time different screening styles that are useful in barring negligible factors so that sweats may concentrate upon just the important bones. Screening styles are used in specific exploration and assiduity have used simulation canons in order to read, to optimize and to make good opinions in the environment of their studies.^[22] Soil microorganisms were insulated to determine their eventuality to produce different enzymes. Microbes were insulated and linked from soil sample. The microbes were screened for enzyme product. Enzyme from microbial source generally meets artificial demand, due to their high yield and thermos stability. Microbial enzyme presents a wide range of characteristics that make them useful for specific operations. Enzyme is natural origin and non-toxic and have great particularity of action hence and cambering about responses not fluently carried out, they work out stylish under mild condition of moderate temperature and near natural pH.^[23] Soil microorganisms named by original screening were subordinated to extracellular enzyme produced by different kinds of microorganisms similar as Fungi, Bacteria, incentive, and Actinomycetes (Devi *et al.* 2008). Organisms have evolved in saline surroundings and are suitable to overcome the dexterous goods and drenching attention. thus, are insulated and screened for extremely halophilic bacteria that can produced high protease exertion at high attention in solid medium. The high protease exertion attained at 5 NaCl. The number of bacteria which are able of producing

antibiotics which include *Bacillus*, *Actinomycetes*^[24] and most *Streptomyces* and most isolates are soil bacteria. Soil is rich in microorganisms which are able of producing antibiotics. The traditional approach is 'arbitrary screening' in which bacteria are isolated grown and their exertion diapason was assessed. Indeed, this has been done for further than 50 years still we're getting results in favour to us and therefore we're sticking with this approach. Soil microorganisms produces enzymes are involved in varied biological processes, e.g. In cell cycle, isolation and other. These enzymes classified as.

1) alkaline phosphatases; 2) high molecular mass acid phosphatases; 3) low molecular mass acid phosphatases; 4) high-flown acid phosphatases; 5) protein phosphatases.^[25]

Alkaline phosphatases are used in enzyme linked immune absorbent assays (ELISA), Non isotopic delving blotting and sequencing system.^[26]

Screening for extracellular amylase producing microbes

Microorganisms are preferred sources of these enzyme because of their quick growth, the limited space needed for their civilization and they can be genetically manipulated to induce new enzymes with altered effects that are desirable for their various operation. Screening system to determine the soil microorganisms. The optimization for webbing system used for the identification of microbial enzyme from other natural source of great significance fungus and bacteria insulated were screen for amylases carboxy methylcelluloses and proteases are extensively used in the assiduity for the manufacture of Medicinals etc. Webbing and insulation of lipase producing microorganisms have the capability to catalysed a Wide variety of response in hydrated and non-hydrated phases.^[27] Microbial lipase has also entered more attention due to their selectivity, stability and substrate, particularity.^[28] Extracellular lipase product by bacteria is impacted by the composition of the growth medium, civilization conditions and numerous physio chemical (pH and temperature) and nutrition facto (carbon, nitrogen, and lipid sources).^[29] A variety of extracellular lipases of bacterial origin with different effects and particularity have been described and characterized. Extracellular lipase was insulated from numerous different bacterial species including *bacillus*^[30] and *Pseudomonas*.^[31] Lipase output by *Acinetobacter* radio resistance under alkaline conditions in the presence of n- hexadecane was estimated.^[32] *Acinetobacter* strain has been insulated from a variety of sources, including, soil and water.^[33,34] Soil microorganisms have been the most important source that has set up numerous operations in the fields of drug, drugstore and husbandry etc. utmost of the antibiotics use for the treatment of various contagious conditions is microbial products. Studies of soil

microorganisms are potentially rich source of unique bioactive substance. Since the discovery of penicillin and other antimicrobial agents by Alexander Fleming in 1928. Some of these are morphological, physical, chemical and mineralogical, characteristics. The soil contains about 10 of organic matter, this has a tremendous effect on soil chemical and physical effects. It corresponds of organic matter similar as carbon, oxygen, hydrogen, nitrogen and Lower amounts of sulphur and other rudiments. The impacts of soil on agrarian productivity and sustainability can be determined by assaying the physical, chemical and natural parameters of the soil. The microbial Product of proteases is preferred further than other source because microbes can be grown and genetically modified fluently.^[35] Protease enzyme can produce eco-friendly products and so they play a vital part in morden biotechnology diligence. The microbial proteases were lacks pathogenicity; thus, they can grow fluently in culture medium and they've wide artificial operation. Microbial protease directly excreted product medium due to their extracellular nature, therefore simplifying sanctification of enzyme as compared to enzyme uprooted from beast and factory. Extracellular proteases catalyse hydrolysis of polypeptides into free amino acid or lower polypeptide chains in the external cell terrain and allow the cell to take up and use product hydrolysis undoable macromolecules similar as collagen, keratin, chitin, cellulose, lignin and casein are biodegraded by microbial extracellular enzymes with the capability to act on thick substrates.

Formats for enzyme- grounded microchips

There are numerous ways in which enzyme assays can be conducted on microchip platforms. similar bioanalytical protocols can be divided to the use of answerable or paralyzed enzymes. Due to the versatility of microchip bias and their negligible reagent consumption, utmost attention has been given to on- chip responses of answerable enzymes. The performing assays generally calculate on mixing and response of the substrate and enzyme) in addition to separations. On- line precolumn, on- column, and post column responses have therefore been considered. The layout for on- chip precolumn and post column enzymatic assays is illustrated in Fig. 1. As common with other microfluidic bias, these channel networks include mixing tees and cross corners for mixing the enzyme reagent and edging in the sample with high reproducibility. The fluid control is fulfilled by electrokinetic pumping through regulation of the voltages applied to the individual budgets (containing the enzyme, sample, or buffer result).

Microchips grounded on paralyzed enzymes

All the formats bandied so far involved result- phase enzymatic responses. It's possible also to

use paralyzed enzyme so they can be used constantly. Enzymes may be paralyzed in columns reactors, on the sensor ('enzyme- electrode biosensor'), or in other formats. paralyzed enzymes have been extensively used in connection to conventional inflow analysers. Karube's group reported on a miniaturized enzyme column, integrated with a micromachined electrochemical inflow cell on a silicon wafer for inflow injection measures of glucose. The immobilization of several enzymes on the same support can also be envisaged.

Enzyme assays and quantitative analysis

The acceleration of response rates by enzymes can constitute up to 20 orders of magnitude compared with noncatalyzed chemical responses to render the development of reactants compatible with the processes of life.^[36] The field of enzymology studies the kinetic and thermodynamic aspects underpinning enzyme- catalysed responses, from substrate list over medium of rate acceleration and the factual chemical step of the catalysed response to product release. Interrogation of these events by devoted biochemical and biophysical assays is the base for successful identification and optimization of webbing successes and lead composites. Generally, during the early phases of medicine discovery, the conditions for biochemical enzyme assays shift as the design transitions from one phase to the coming (Fig. 2). originally, during the exploratory target assessment phase, one needs to characterize the target enzyme. To enable a full medicine discovery program, one needs to characterize the mortal or pathogen variants of interest, but homologs deduced from colourful species that might be used in in vivo studies at a after stage are also delved. This characterization should number the choice of applicable forms of the target enzyme and possible off- or counter-targets with regard to sphere structure, tone- or hetero association, post-translational revision, reliance on non-protein aceousco-factors and source, to define the enzyme reagents demanded for latterly in vitro high-outturn webbing (HTS) juggernauts and webbing work- up. At the same time, it's important to estimate various biochemical assay formats with different forms of the enzymes and substrates of interest as well as the proper selection of response conditions, similar as buffer composition and temperature, to insure sufficient specific exertion and stability of the target enzyme during the webbing crusade.^[37] The geste of any reference composites and primary successes in the assay format of choice needs to be well characterized before and following HTS, independently. Given their specific physicochemical parcels, small- patch composites can intrude with assay factors in unanticipated manner or with the readout principle of the assay. A thorough description of emulsion features and substructures that have empirically determined arrears for hindrance let to the description of Pan-Assay Interference Compounds

(PAICs) or, by using a vaticination tool grounded on machine literacy, composites snooping with an Assay Technology (CIAT).^[38,39] Following an annotated ontology of primary actives linked in a screen, the members of the primary megahit list can be divided in true cons acting on the molecular target, which comprise the sought- after true successes and also false successes with unwanted molecular mode of action (MMoA), as opposed to readout modulators, which intrude with the discovery principle but not directly with the target.^[40] Biophysical styles with readouts that are orthogonal to that used in the primary HTS have the eventuality to deliver unequivocal information on reference and hit emulsion parcels and direct engagement with the target.^[41–43] With optimized assay formats, the crucial enzyme parameters, including parameters describing substrate recognition (KM) and development (kcat, Vmax) for enzymes adhering Michaelis – Menten kinetics and, if demanded, more complex response mechanisms, can be illustrated. The mechanistic understanding of the enzyme- catalysed response determines the layout of the assay used in HTS. This is because the choice of attention for enzyme, substrate, and emulsion as well as the time- point of the dimension relative to the rates of substrate development and product conformation can introduce a bias regarding the perceptivity of the assay to impediments with different MMoA. For illustration, conditions with high substrate attention will elect against competitive impediments but favor the conformation of ternary complexes of enzyme, substrate, and apparent uncompetitive impediments, whereas a low substrate attention will allow for list of indeed fairly weak competitive impediments. Compared with single substrate responses, bi-substrate responses earn special attention with regard to choosing balanced response conditions because one substrate might impact the affinity of the enzyme toward the other.^[44] Therefore, for HTS, it's important to optimize the enzyme assay not only to a high degree of robustness in terms of delicacy and reproducibility as described by the well- known descriptor z ^[45], but also with respect to biochemical validity and applicability of the measured data.



Figure 2: Applications of enzymology in the early phases of drug discovery (see main text and glossary for explanation of acronyms).

Outlook new technologies and new modalities

The field of enzymology remains an integral part of ultramodern medicine discovery, which is reflected by the nonstop treatment of the content and development of tools. In fact, an ever-adding space of druggable targets requires a matching force of technologies and remedial modalities. Although utmost established enzyme impediments are competitive small- patch impediments, an adding number of exemplifications of non-competitive(allosteric) and uncompetitive impediments are under study as investigational medicines (www.clinicaltrials.gov/) or are in clinical use.^[46,47] The arrival and refinement of new technologies and modalities, including chemical proteomics, proteolysis- targeting fantasies (a.k.a. beguilers), activation or inhibition of enzyme function by small moles, remedial antibodies, macrocyclic peptides, enzyme relief remedy, and pharmacological chaperones has stimulated a swell in medicine discovery sweats targeting enzymes.^[48–57] Recent exemplifications illustrate the donation of enzymology to chancing innovative modalities and modes of action, similar as an uncompetitive inhibitory antibody binding to an epitope distant to the orthostatic substrate binding point of the ecto- ATPase CD39, or the case of nonclassical uncompetitive inhibition of the allosteric activation of the guanine exchange factor EPAC1(109). Bringing together generalities from classical enzymology with these new approaches will grease the discovery of new remedial modifiers of enzyme exertion.

REFERENCES

1. Hopkins AL, Groom CR: The druggable genome. *Nature Reviews Drug Discovery*, 2002; 1: 727-730.
2. Manly SP: In vitro biochemical screening. *JBiomol Screen*, 1997; 2: 197-199.

3. Chung TDY, Murphy DJ: Enzyme screens. In Seethala R, Fernandes PB (eds): Handbook of Drug Screening. New York: Marcel Dekker, 2001; 283-311.
4. Walters W, Namchuk M: Designing screens: how to make your hits a hit. *Nature Reviews Drug Discovery*, 2003; 2: 259-266.
5. Segel IH: Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Hoboken, NJ: Wiley-Interscience, 1975.
6. Walsh C: Enzymatic Reaction Mechanisms. New York: W. H. Freeman, 1979.
7. Copeland RA: Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis. 2nd ed. New York: John Wiley & Sons, 2000.
8. Spector DL, Goldman RD, Leinwand LA: Kinetics for kinases. In DL Spector, RD Goldman, LA Leinwand (eds): *Cells: A Laboratory Manual*. New York: Cold Spring Harbor Laboratory Press, 1997; 30: 1-30.9.
9. Zhang J-H, Chung TDY, Oldenberg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biolmol Screen*, 1999; 4: 67-73.
10. Macarron R, Hertzberg RP: Design and implementation of high throughput screening assays. In Jansen WP (ed): *High Throughput Screening Methods and Protocols*. Totowa, NJ: Humana, 2002; 1-29.
11. Figeys, D., Pinto, D., *Anal. Chem*, 2000; 71: 330A-335A.
12. Freemantle, M., *Chem. Eng. News*, 1999; 27-36.
13. Kutter, J. P., *Trends Anal. Chem*, 2000; 19: 352-363.
14. Hansen, E. H., *Anal. Chim. Acta*, 1989; 216: 257-273.
15. Wu, D., Regnier, F., *Anal. Chem*, 1993; 65: 2029-2035.
16. Regnier, F., He, B., Lin, S., Busse, J., *Trends Biotechnol*, 1999; 17: 101-106.
17. Waterval, J. C., Lingeman, H., Bult, A., Underberg, W. J., *Electrophoresis*, 2000; 21: 4029-4045.
18. Barton. 2001. Designing simulation experiments, 2001. Winter simulation conference in: Peters, B.A., Medeiros, D.J., Rohrer, M.W., (Eds), 47-57.
19. Kleijnen, J.P.C., 2004. An overview of the design and analysis, *European Journal of operational research*.
20. Welch, W. J., Buck, R. J., et al. 1992. Screening predicting and computer experiments. *Technometrics*, 34: 15-25.
21. ISSN 2230- 9926 *International Journal of Development Research*, October, 2017; 07(10): 16398-16400, <http://www.journalijdr.com> Citation Meena Seema and Prahlad Dube. 2017.

- “A review on webbing styles for extracellular enzymes”, International Journal of Development Research, 7(10): 16398- 16400.
22. Azarian, A., Vasseur, O., et al., 2011. Sensitivity analysis of interference optical systems by numerical design. Journal de la SFDS, 152: 1: 118-130.
 23. S. B. Oyeleke, B.S. Manga: essential of laboratory practical's in microbiology 1st edition, Tobest publisher, Niger state, 2008; 36-58.
 24. Abdulkadir, M. et al. 2012. Screening and isolation of the soil bacteria for ability to produce antibiotics. Eur. J. Appl. Sci, 4(5): 211-215.
 25. Vincent J.B. et al. 1992. Hydrolysis of phosphate mono esters a biological problem with multiple chemical solutions Trends Biochem. Sci, 17: 105-110.
 26. Dong, G. et al. 1997. Purification and characterization of alkaline phosphatase from *Thermotoga neaplitana*. Enzyme microbiology Technology, 21: 335-340.
 27. Saxena, R.K., et al. 2003. Purification strategies for microbial lipases. J. Microbiology, method, 52: 1-18.
 28. Treichel H, Oliveria D., et al. 2010. A review on microbial lipases production food Bioprocess Technology, 3: 182-196.
 29. Jaeger KE, Ransac S., et al., 1984. Bacterial lipases. FEMS microbiology Rev, 15: 29- 63.
 30. Ertugrul S., Domez G., Takas S 2007. Isolation lipases producing *Bacillus* sp. from olive mill waste water and improving its enzyme activity J. Hazard. Mater, 149: 720- 724.
 31. Kiran. G.S, et al., 2008. Optimization of extra cellular Psychriophilic alkaline lipase Produce by marine *pseudomonas* sp. (MS1057). Bioprocess Biosyst. Eng, 31: 483- 492.
 32. Kasana RC, et al. 2008. Isolation and identification of a psychotropic *Acinetobacter* sp. CR9 and characterization of its alkaline lipases J. Basic microbiology, 48: 207-212.
 33. Chen S J, et al. 1998. Production of alkaline lipases by *Acinetobacter redioresistens* J. Ferment. Bioeng, 86: 306- 312.
 34. Blaise CR, Armstrong JB (1973). Lypolytic bacteria in the Ottawa River. Appl.Microbiol, 26: 733-740.
 35. Bompensier S, Gonzalez R, et al., 1996. Purification of lipase from *Acinetobacter calcoaceticus* AAC 323-1. BY hydrophobic interaction method. Biotechnology Appl. Biochem, 23: 77-81.
 36. Sharma kumar A. et al. 2015. Optimization of proteases production from bacterial from soil Appl. Research Journal, 1: 388-394.
 37. Wolfenden, R. and Snider, M.J. (2001) The depth of chemical time and the power of enzymes as catalysts. Acc Chem. Res, 34: 938–945.

38. Selwyn, M.J. (1965) A simple test for inactivation of an enzyme during assay. *Biochem. Biophys. Acta*, 105: 193–195.
39. Baell, J.B. and Holloway, G.A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.*, 53: 2719–2740.
40. David, L. et al. (2019) Identification of compounds that interfere with high-throughput screening assay technologies. *ChemMedChem*, 14(20): 1795–1802.
41. Baell, J.B. and Nissink, J.W.M. (2018) Seven-year itch: pan-assay interference compounds (PAINS) in 2017-utility and limitations. *ACS Chem. Biol.*, 13: 36–44.
42. Gossert, A.D. (2019) Assessing molecular interactions with biophysical methods using the validation cross. *Biochem. Soc. Trans.*, 47: 63–76.
43. Genick, C.C. and Wright, S.K. (2017) Biophysics: for HTS hit validation, chemical lead optimization, and beyond. *Expert Opin. Drug Discovery*, 12: 897–907.
44. Holdgate, G. et al. (2013) Biophysical methods in drug discovery from small molecule to pharmaceutical. *Methods Mol. Biol.*, 1008: 327–355.
45. Yang, J. et al. (2009) Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. *J. Biomol. Screen*, 14: 111–120.
46. Zhang, J.H. et al. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen*, 4: 67–73.
47. Alexander, S.P.H. et al. (2019) THE Concise Guide to Pharmacology 2019/20: Enzymes. *Br. J. Pharmacol.*, 176: S297–S396.
48. Wishart, D.S. et al. (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.*, 46(D1): D1074–D1082.
49. Cisar, J.S. et al. (2018) Identification of ABX-1431, a selective inhibitor of monoacylglycerol lipase and clinical candidate for treatment of neurological disorders. *J. Med. Chem.*, 61(20): 9062–9084.
50. Cravatt, B.F. et al. (2008) Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. *Annu. Rev. Biochem.*, 77: 383–414.
51. Fisher, S.L. and Phillips, A.J. (2018) Targeted protein degradation and the enzymology of degraders. *Curr. Opin. Chem. Biol.*, 44: 47–55.
52. Wu, T. et al. (2020) Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. *Nat. Struct. Mol. Biol.*, 27: 605–614.
53. Kitazawa, T. et al. (2012) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. *Nat. Med.*, 18: 1570–1574.

54. Lopez, T. et al. (2019) Functional selection of protease inhibitory antibodies. *Proc. Natl. Acad. Sci. U. S. A*, 116(33): 16314–16319.
55. Yang, J. et al. (2020) Macrocyclic peptides uncover a novel binding mode for reversible inhibitors of LSD1. *ACS Omega*, 5: 3979–3995.
56. Desnick, R.J. and Schuchman, E.H. (2012) Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. *Annu. Rev. Genomics Hum. Genet*, 13: 307–335.
57. Convertino, M. et al. (2016) Pharmacological chaperones: design and development of new therapeutic strategies for the treatment of conformational diseases. *ACS Chem. Biol*, 11: 1471–1489.
58. Grewal, A.S. et al. (2020) Recent developments in medicinal chemistry of allosteric activators of human glucokinase for Type 2 diabetes mellitus therapeutics. *Curr. Pharm. Des*, 26(21): 2510–2552.